Results 101 to 110 of about 471 (127)

Studies on Enmetazobactam Clarify Mechanisms of Widely Used β-Lactamase Inhibitors [PDF]

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2022
Significance Microbial resistance to β-lactam antibiotics mediated by β-lactamase–catalyzed hydrolysis is a major global health concern. Penam sulfones, which are structurally related to penicillins, inhibit clinically important serine β-lactamases (SBLs) by forming transiently stable covalent complexes, thereby protecting β-lactam ...
Carol V. Robinson   +2 more
exaly   +5 more sources

Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined With Cefepime in a Neutropenic Murine Thigh Infection Model.

open access: yesAntimicrobial Agents and Chemotherapy, 2020
Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants.
Fabian Bernhard   +2 more
exaly   +4 more sources

Liquid Chromatography–Tandem Mass Spectrometry for the Simultaneous Quantitation of Enmetazobactam and Cefepime in Human Plasma

open access: yesJournal of Pharmaceutical and Biomedical Analysis, 2019
A simple ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the simultaneous analysis enmetazobactam (also known as AAI101) and cefepime in human plasma. Sample preparation was based on protein precipitation with acetonitrile. Separation was performed on Acquity BEH HILIC column (50 mm × 
M, Mameli   +7 more
exaly   +6 more sources

Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor

Annals of Pharmacotherapy
Objective: To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT). Data Sources: A literature search was conducted using ...
Kelly L Covert, Cameron Lanier
exaly   +3 more sources

In complicated UTI or pyelonephritis, cefepime–enmetazobactam increased success vs. piperacillin–tazobactam at 14 d

Annals of Internal Medicine, 2023
Kaye KS, Belley A, Barth P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328:1304-14. 36194218.
openaire   +2 more sources

Cefepime/Enmetazobactam: First Approval

Drugs
Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cephalosporin and an extended-spectrum β-lactamase (ESBL) inhibitor, is being developed by Allecra Therapeutics and ADVANZ PHARMA for the treatment of infections caused by multi-drug-resistant (MDR) Gram-negative bacteria. In February 2024,
openaire   +2 more sources

Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

The Medical Letter on Drugs and Therapeutics
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms.
openaire   +2 more sources

Invention of Enmetazobactam: An Indian Triumph in Antimicrobial Drug Discovery

ACS Infectious Diseases
The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India.
openaire   +2 more sources

Cefepime Enmetazobactam: A Carbapenem Sparing Strategy Against ESBL Producing Enterobacterales

International Journal of Health Sciences and Research
Background & Objectives: The rise of antimicrobial resistance, particularly among Gram-negative pathogens producing extended-spectrum β-lactamases (ESBLs), is a major global concern. Carbapenems remain the mainstay of therapy but their overuse has led to the emergence of carbapenemases, emphasizing the need for carbapenem-sparing alternatives ...
Stefy Baby   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy